Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT324 and BNT327 in Advanced Lung Cancer
NCT06892548Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- May 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of db-1311 and pumitamig in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (8 arms), sponsored by BioNTech SE. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 90 days and 2 more. Started May 2025; status: recruiting.
02
Drugs
db-1311pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06892548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892548.